aTyr Pharma (LIFE) Tops Q2 EPS by 6c

aTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71).

Financial Guidance

As of June 30, 2016, we had $96.6 million in cash, cash equivalents and investments and 23.7 million shares of common stock outstanding.

We currently expect that our cash, cash equivalents and investments will be sufficient to fund our anticipated operations into 2018.

For earnings history and earnings-related data on aTyr Pharma (LIFE) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Cooper Cos. (COO) Tops Q3 EPS by 3c, Offers Guidance
• RH (RH) Tops Q2 EPS by $2.31